Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences (SATIS-Fab)

Status: Completed
Location: See all (15) locations...
Intervention Type: Behavioral
Study Type: Observational
SUMMARY

In the shared decision-making process, patients should express their expectations and preferences regarding treatment to the physician. A specific questionnaire addressing needs and expectations of Fabry patients has been built at the initiative of Amicus. In addition, this questionnaire also evaluates the benefit of treatment from the patient's perspective. Nothing is known until now on patient's expectations, potential clustering of patients regarding their expectations and evaluation of treatment benefit from the patients perspective. Study objectives are differentiated according to the study phase (inclusion and follow-up). At inclusion, the primary objective is to cluster patients according to their needs and expectations regarding treatment. During follow-up, the primary objective is to evaluate treatment benefit in relation with patients needs and expectations.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:

• Patients ≥ 16 years old

• Diagnosed with Fabry disease

• With amenable mutation

• Decision by clinician to start or pursue ongoing ERT or migalastat

• Non-opposition form to participate in the study signed

Locations
Other Locations
France
CHU d'Angers
Angers
CHU Pellegrin
Bordeaux
Hôpital Côte de Nacre
Caen
CHU de Dijon
Dijon
CHRU de Lille
Lille
Hôpital Femme Mère Enfant
Lyon
Hôpital de la Conception
Marseille
CHU de Nantes
Nantes
Groupe Hospitalier Diaconesses Croix Saint-Simon
Paris
Hopital Tenon
Paris
CHU de Rennes
Rennes
CHU de Rouen
Rouen
CHU de Strasbourg
Strasbourg
CHU de Toulouse
Toulouse
CHU de Tours
Tours
Time Frame
Start Date: 2019-04-04
Completion Date: 2023-01-30
Participants
Target number of participants: 69
Treatments
Whole cohort
The whole cohort will be divided into clusters according to patients expectations and preferences regarding their treatment
Related Therapeutic Areas
Sponsors
Leads: Amicus Therapeutics France SAS

This content was sourced from clinicaltrials.gov